Show simple item record

dc.contributor.authorOttoni, MP
dc.contributor.authorRicciardone, JD
dc.contributor.authorNadimpalli, A
dc.contributor.authorSingh, S
dc.contributor.authorKatsomya, AM
dc.contributor.authorPokoso, LM
dc.contributor.authorPetrucci, R
dc.date.accessioned2020-12-04T18:49:33Z
dc.date.available2020-12-04T18:49:33Z
dc.date.issued2020-12-01
dc.date.submitted2002-12-04
dc.identifier.urihttp://hdl.handle.net/10144/619783
dc.description.abstractBackground Few fetuses survive childbirth when the mother is positive for Ebola virus, with almost all being miscarried or stillborn, or dying shortly after birth. Before 2019, only two infants had been reported surviving past 28 days, of whom one tested positive for Ebola virus and subsequently received experimental therapies. Little is understood regarding the care of surviving neonates born to Ebola virus-positive mothers in the postnatal period and how novel anti-Ebola virus therapies might affect neonatal outcomes. Methods In this case series, we report on two neonates liveborn during the 2018–20 North Kivu Ebola epidemic in the Democratic Republic of the Congo who, along with their Ebola virus-positive mothers, received investigational monoclonal antibody treatment (mAB114 or REGN-EB3) as part of a randomised controlled trial (NCT03719586). Findings Both infants were born Ebola-negative and progressed well while in the Ebola Treatment Centre. Neither neonate developed evidence of Ebola virus disease during the course of the admission, and both were Ebola-negative at 21 days and remained healthy at discharge. Interpretation To our knowledge these neonates are the first documented as Ebola virus-negative at birth after being born to Ebola virus-positive mothers, and only the third and fourth neonates ever documented to have survived into infancy. Although no conclusions can be drawn from this small case series, and further research is required to investigate the neonatal effects of antibody therapies, these cases warrant review regarding whether post-delivery antibody therapy should be considered for all liveborn neonates of Ebola virus-positive mothers. In the context of a low resource setting, where survival of low-birthweight infants is poor, these cases also highlight the importance of adequate neonatal care.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsWith thanks to Elsevier.en_US
dc.titleEbola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case seriesen_US
dc.identifier.journalThe Lancet Child & Adolescent Healthen_US
refterms.dateFOA2020-12-05T02:09:19Z


Files in this item

Thumbnail
Name:
Ottoni et al 2020 Ebola-negative ...
Size:
102.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record